Skip to content

Study · Not a test of the peptide alone · 2016

10 results

Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.

Quan H, Zhang H, Wei W, Fang T

Journal of diabetes and its complications15 Jan 2016Cited by 51 (Europe PMC)

PMID26873871 (opens in a new tab)DOI10.1016/j.jdiacomp.2016.01.013 (opens in a new tab)PepBankPUB-26873871
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 01HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In newly diagnosed type 2 diabetes, exenatide plus metformin produced mean weight losses of 8.2 kg in women and 4.6 kg in men.

    In plain wordsWomen receiving exenatide plus metformin lost more weight than men receiving the same treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWeight loss
    Study

    n = 105

    Comparator
    Male patients
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight loss
    8.2 kg
    female patients
    Weight loss
    4.6 kg
    male patients

    Source sentences

    Summary
    There was an average of 8.2 ± 2.4 kg and 4.6 ± 2.3 kg weight loss in female and male patients, respectively.
    1 context sentence
    Summary · context
    One hundred and five overweight and obesity patients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 02HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In newly diagnosed type 2 diabetes, exenatide plus metformin improved insulin sensitivity more in women than men.

    In plain wordsExenatide plus metformin improved insulin sensitivity more in women than men.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInsulin sensitivity
    Study

    n = 105

    Comparator
    Male patients
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The combined therapy showed better effects on female than male patients for improving insulin sensitivity and serum lipid profile, reducing insulin resistance, increasing adiponectin levels, and decreasing the levels of HbA1c, BMI, resistin, TNF-alpha and C-reactive protein (P<0.05).
    1 context sentence
    Summary · context
    One hundred and five overweight and obesity patients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 03HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In newly diagnosed type 2 diabetes, exenatide plus metformin improved serum lipid profiles more in women than men.

    In plain wordsExenatide plus metformin improved blood lipid profiles more in women than men.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedSerum lipid profile
    Study

    n = 105

    Comparator
    Male patients
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    The combined therapy showed better effects on female than male patients for improving insulin sensitivity and serum lipid profile, reducing insulin resistance, increasing adiponectin levels, and decreasing the levels of HbA1c, BMI, resistin, TNF-alpha and C-reactive protein (P<0.05).
    1 context sentence
    Summary · context
    One hundred and five overweight and obesity patients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 04HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In newly diagnosed type 2 diabetes, exenatide plus metformin reduced insulin resistance more in women than men.

    In plain wordsExenatide plus metformin reduced insulin resistance more in women than men.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInsulin resistance
    Study

    n = 105

    Comparator
    Male patients
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The combined therapy showed better effects on female than male patients for improving insulin sensitivity and serum lipid profile, reducing insulin resistance, increasing adiponectin levels, and decreasing the levels of HbA1c, BMI, resistin, TNF-alpha and C-reactive protein (P<0.05).
    1 context sentence
    Summary · context
    One hundred and five overweight and obesity patients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  5. 05HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In newly diagnosed type 2 diabetes, exenatide plus metformin increased adiponectin more in women than men.

    In plain wordsExenatide plus metformin increased adiponectin more in women than men.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAdiponectin
    Study

    n = 105

    Comparator
    Male patients
    Outcome group
    Inflammation markers · Metabolic and weight

    Source sentences

    Summary
    The combined therapy showed better effects on female than male patients for improving insulin sensitivity and serum lipid profile, reducing insulin resistance, increasing adiponectin levels, and decreasing the levels of HbA1c, BMI, resistin, TNF-alpha and C-reactive protein (P<0.05).
    1 context sentence
    Summary · context
    One hundred and five overweight and obesity patients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  6. 06HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In newly diagnosed type 2 diabetes, exenatide plus metformin reduced HbA1c more in women than men.

    In plain wordsExenatide plus metformin reduced HbA1c more in women than men.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c
    Study

    n = 105

    Comparator
    Male patients
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The combined therapy showed better effects on female than male patients for improving insulin sensitivity and serum lipid profile, reducing insulin resistance, increasing adiponectin levels, and decreasing the levels of HbA1c, BMI, resistin, TNF-alpha and C-reactive protein (P<0.05).
    1 context sentence
    Summary · context
    One hundred and five overweight and obesity patients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  7. 07HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In newly diagnosed type 2 diabetes, exenatide plus metformin reduced BMI more in women than men.

    In plain wordsExenatide plus metformin reduced BMI more in women than men.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBMI
    Study

    n = 105

    Comparator
    Male patients
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    The combined therapy showed better effects on female than male patients for improving insulin sensitivity and serum lipid profile, reducing insulin resistance, increasing adiponectin levels, and decreasing the levels of HbA1c, BMI, resistin, TNF-alpha and C-reactive protein (P<0.05).
    1 context sentence
    Summary · context
    One hundred and five overweight and obesity patients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  8. 08HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In newly diagnosed type 2 diabetes, exenatide plus metformin reduced resistin more in women than men.

    In plain wordsExenatide plus metformin reduced resistin more in women than men.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseResistin
    Study

    n = 105

    Comparator
    Male patients
    Outcome group
    Inflammation markers · Metabolic and weight

    Source sentences

    Summary
    The combined therapy showed better effects on female than male patients for improving insulin sensitivity and serum lipid profile, reducing insulin resistance, increasing adiponectin levels, and decreasing the levels of HbA1c, BMI, resistin, TNF-alpha and C-reactive protein (P<0.05).
    1 context sentence
    Summary · context
    One hundred and five overweight and obesity patients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  9. 09HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In newly diagnosed type 2 diabetes, exenatide plus metformin reduced TNF-alpha more in women than men.

    In plain wordsExenatide plus metformin reduced TNF-alpha more in women than men.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTNF-alpha
    Study

    n = 105

    Comparator
    Male patients
    Outcome group
    Inflammation markers · Metabolic and weight

    Source sentences

    Summary
    The combined therapy showed better effects on female than male patients for improving insulin sensitivity and serum lipid profile, reducing insulin resistance, increasing adiponectin levels, and decreasing the levels of HbA1c, BMI, resistin, TNF-alpha and C-reactive protein (P<0.05).
    1 context sentence
    Summary · context
    One hundred and five overweight and obesity patients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  10. 10HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In newly diagnosed type 2 diabetes, exenatide plus metformin reduced C-reactive protein more in women than men.

    In plain wordsExenatide plus metformin reduced C-reactive protein more in women than men.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseC-reactive protein
    Study

    n = 105

    Comparator
    Male patients
    Outcome group
    Inflammation markers · Metabolic and weight

    Source sentences

    Summary
    The combined therapy showed better effects on female than male patients for improving insulin sensitivity and serum lipid profile, reducing insulin resistance, increasing adiponectin levels, and decreasing the levels of HbA1c, BMI, resistin, TNF-alpha and C-reactive protein (P<0.05).
    1 context sentence
    Summary · context
    One hundred and five overweight and obesity patients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.